Clinical Trial Update: The MARS® Albumin Dialysis System in Patients With Fulminant and Subfulminant Hepatic Failure [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the MARS Albumin Dialysis System in patients with fulminant and subfulminant hepatic failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fulminant Hepatic Failure
• Subfulminant Hepatic Failure

Drugs mentioned

• MARS Albumin Dialysis System

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Hepatitis | Phase 3 | Status: COMPLETED